Download Sample
Add to CartViscosupplementation Market
By Dosage;
Single Injection, Three Injection, and Five InjectionBy Arthritis Type;
Osteoarthritis and Rheumatoid ArthritisBy Application;
Knee Osteoarthritis, Hip Osteoarthritis, Shoulder Osteoarthritis, and OthersBy End User;
Hospitals, Ambulatory Surgical Centers, and OthersBy Geography;
North America, Europe, Asia Pacific, Middle East & Africa, and Latin America - Report Timeline (2021 - 2031)Viscosupplementation Market Overview
Viscosupplementation Market (USD Million)
Viscosupplementation Market was valued at USD 3,936.51 million in the year 2024. The size of this market is expected to increase to USD 6,999.72 million by the year 2031, while growing at a Compounded Annual Growth Rate (CAGR) of 8.6%.
Viscosupplementation Market
*Market size in USD million
CAGR 8.6 %
| Study Period | 2025 - 2031 |
|---|---|
| Base Year | 2024 |
| CAGR (%) | 8.6 % |
| Market Size (2024) | USD 3,936.51 Million |
| Market Size (2031) | USD 6,999.72 Million |
| Market Concentration | Medium |
| Report Pages | 390 |
Major Players
- Fidia Farmaceutici s.p.a
- Ferring Pharmaceuticals
- Anika Therapeutics Inc
- Bioventus LLC
- Sanofi SA
Market Concentration
Consolidated - Market dominated by 1 - 5 major players
Viscosupplementation Market
Fragmented - Highly competitive market without dominant players
The viscosupplementation market is expanding as more individuals seek effective solutions for joint degeneration without resorting to surgery. As osteoarthritis becomes more common due to aging and lifestyle factors, over 55% of affected individuals are turning to viscosupplements for relief. These injections are favored for their ability to ease joint pain and improve mobility with minimal procedural risk.
Dominance of Hyaluronic Acid-Based Formulations
A significant portion of the market is driven by hyaluronic acid-based injections, known for enhancing joint lubrication and reducing inflammation. These options account for nearly 60% of viscosupplementation treatments, reflecting their strong therapeutic profile and widespread acceptance in clinical practice. Their compatibility with early-stage management has further encouraged adoption.
Product Advancements Driving Market Appeal
Innovations in viscosupplementation delivery systems, such as single-dose and multi-dose options, are helping tailor treatment to individual needs. More than 30% of recent product developments emphasize ease of use and improved outcomes, making them attractive to healthcare providers and patients alike. These advancements are elevating both treatment efficiency and user experience.
Preventive Joint Care Influencing Market Growth
With awareness campaigns highlighting the importance of early orthopedic intervention, more patients are proactively seeking viscosupplementation. Currently, about 45% of individuals experiencing joint discomfort are opting for these treatments as a preventive measure. This shift toward early action is fostering steady growth in the market.
Viscosupplementation Market Recent Developments
-
In December 2021, Avanos Medical acquired OrthogenRx, integrating its hyaluronic acid viscosupplement therapies into Avanos’s chronic pain portfolio to expand osteoarthritis treatment options.
-
In August 2021, Seikagaku Corporation launched HyLink, a high‑viscosity, single‑injection hyaluronic acid viscosupplement designed to enhance joint lubrication and pain relief in knee osteoarthritis.
Viscosupplementation Market Segment Analysis
In this report, the Viscosupplementation Market has been segmented by Dosage, Arthritis Type, Application, End User and Geography.
Viscosupplementation Market, Segmentation by Dosage
The Viscosupplementation Market has been segmented by Dosage into Single Injection, Three Injection and Five Injection.
Single Injection
Single Injection treatments dominate the viscosupplementation market, contributing approximately 52% of global revenue in 2022. This segment is driven by the growing preference for convenience and reduced procedural frequency. The ability to provide effective symptom relief with fewer injections appeals to both patients and healthcare providers.
Three Injection
Three Injection treatments account for around 34% of the viscosupplementation market. This regimen provides a balance between treatment efficacy and cost-effectiveness, making it a popular option for moderate osteoarthritis cases. The established clinical benefits of three-injection series support ongoing demand.
Five Injection
Five Injection treatments hold an estimated 14% share of the viscosupplementation market. This regimen is typically used in severe cases requiring enhanced symptom management over an extended period. The availability of high-molecular-weight hyaluronic acid products supports the effectiveness of this segment.
Viscosupplementation Market, Segmentation by Arthritis Type
The Viscosupplementation Market has been segmented by Arthritis Type into Osteoarthritis, and Rheumatoid Arthritis.
Osteoarthritis
Osteoarthritis holds the largest share of the viscosupplementation market, contributing approximately 85% of global revenue in 2022. The high prevalence of osteoarthritis globally, especially among the aging population, drives strong demand. Viscosupplementation treatments are widely used to manage symptoms and improve joint mobility in patients with knee and hip osteoarthritis.
Rheumatoid Arthritis
Rheumatoid Arthritis accounts for around 15% of the viscosupplementation market. Although viscosupplementation is less commonly used for rheumatoid arthritis compared to osteoarthritis, its application in certain cases to reduce joint pain and improve mobility is gaining attention. Combination therapies and individualized treatment plans contribute to market demand in this segment.
Viscosupplementation Market, Segmentation by Application
The Viscosupplementation Market has been segmented by Application into Knee Osteoarthritis, Hip Osteoarthritis, Shoulder Osteoarthritis and Others.
Knee Osteoarthritis
Knee Osteoarthritis dominates the viscosupplementation market, contributing approximately 72% of global revenue in 2022. This dominance is driven by the high prevalence of knee osteoarthritis, particularly among elderly patients. Viscosupplementation therapies are widely used to relieve joint pain, improve mobility, and delay joint replacement surgeries.
Hip Osteoarthritis
Hip Osteoarthritis accounts for around 14% of the viscosupplementation market. The application of viscosupplementation in hip joints is growing, offering relief from pain and improving quality of life for patients with moderate to severe symptoms. Increased awareness and improved access to advanced treatment options support this segment’s growth.
Shoulder Osteoarthritis
Shoulder Osteoarthritis holds an estimated 8% share of the viscosupplementation market. Although less common than knee or hip osteoarthritis, viscosupplementation treatments provide an effective option for pain management and mobility improvement in patients with shoulder joint issues. This segment is expected to grow as clinical evidence supporting its efficacy expands.
Others
The "Others" category, which includes ankle and temporomandibular joint osteoarthritis, contributes around 6% of the viscosupplementation market. Although relatively small, this segment addresses specialized treatment needs and supports the market’s diversification across various joint types.
Viscosupplementation Market, Segmentation by End User
The Viscosupplementation Market has been segmented by End User into Hospitals, Ambulatory Surgical Centers, and Others.
Hospitals
Hospitals dominate the viscosupplementation market, contributing approximately 60% of global revenue in 2022. These facilities offer comprehensive diagnostic and treatment services for osteoarthritis and related conditions, supported by the availability of specialized equipment and skilled healthcare professionals. The rising volume of inpatient procedures drives sustained demand in this segment.
Ambulatory Surgical Centers
Ambulatory Surgical Centers (ASCs) account for around 25% of the viscosupplementation market. ASCs offer cost-effective and efficient care for patients requiring single-injection or multi-injection therapies. Their ability to provide outpatient treatments with shorter recovery times supports increasing adoption in this segment.
Others
The "Others" category, including physician offices, specialty clinics, and home care settings, holds an estimated 15% share of the viscosupplementation market. These settings cater to patients seeking personalized care and offer flexibility in treatment administration. Growing awareness of non-hospital-based care options supports market expansion.
Viscosupplementation Market, Segmentation by Geography
In this report, the Viscosupplementation Market has been segmented by Geography into five regions; North America, Europe, Asia Pacific, Middle East and Africa and Latin America.
Regions and Countries Analyzed in this Report
Viscosupplementation Market Share (%), by Geographical Region
North America
North America leads the viscosupplementation market, accounting for approximately 41% of global revenue in 2022. The region's dominance is driven by high prevalence of osteoarthritis, advanced healthcare infrastructure, and strong presence of key market players. Increasing awareness and availability of advanced viscosupplementation treatments further fuel growth.
Europe
Europe holds around 29% of the viscosupplementation market. The region benefits from rising demand for minimally invasive therapies, expanding geriatric population, and supportive healthcare policies. Growing emphasis on early diagnosis and treatment of osteoarthritis drives this segment.
Asia Pacific
Asia Pacific accounts for an estimated 19% share of the viscosupplementation market. Rapidly improving healthcare infrastructure, increasing chronic disease prevalence, and rising awareness of advanced treatments fuel growth in this region. Countries such as China, India, and Japan contribute significantly due to expanding aging populations and rising healthcare investments.
Middle East and Africa
Middle East and Africa contribute approximately 6% of the viscosupplementation market. Growth is supported by expanding healthcare access, rising government investments in healthcare technology, and growing demand for non-surgical treatment options. Partnerships with market leaders further enhance market development.
Latin America
Latin America holds around 5% of the viscosupplementation market. Growth drivers include rising osteoarthritis prevalence, increasing healthcare investments, and improving access to advanced viscosupplementation therapies. Efforts to strengthen healthcare systems and expand minimally invasive treatment options contribute to growth.
Viscosupplementation Market Trends
This report provides an in depth analysis of various factors that impact the dynamics of Viscosupplementation Market. These factors include; Market Drivers, Restraints and Opportunities Analysis.
Comprehensive Market Impact Matrix
This matrix outlines how core market forces—Drivers, Restraints, and Opportunities—affect key business dimensions including Growth, Competition, Customer Behavior, Regulation, and Innovation.
| Market Forces ↓ / Impact Areas → | Market Growth Rate | Competitive Landscape | Customer Behavior | Regulatory Influence | Innovation Potential |
|---|---|---|---|---|---|
| Drivers | High impact (e.g., tech adoption, rising demand) | Encourages new entrants and fosters expansion | Increases usage and enhances demand elasticity | Often aligns with progressive policy trends | Fuels R&D initiatives and product development |
| Restraints | Slows growth (e.g., high costs, supply chain issues) | Raises entry barriers and may drive market consolidation | Deters consumption due to friction or low awareness | Introduces compliance hurdles and regulatory risks | Limits innovation appetite and risk tolerance |
| Opportunities | Unlocks new segments or untapped geographies | Creates white space for innovation and M&A | Opens new use cases and shifts consumer preferences | Policy shifts may offer strategic advantages | Sparks disruptive innovation and strategic alliances |
Drivers, Restraints and Opportunity Analysis
Drivers
- Growing geriatric population worldwide
- Advancements in Viscosupplement Formulations
-
Increasing Preference for Minimally Invasive Treatment Options - A significant driver of the viscosupplementation market. Patients with knee osteoarthritis increasingly seek alternatives to joint replacement surgery that involve less pain, lower risk, and faster recovery. Viscosupplementation, which involves injecting hyaluronic acid directly into the joint, offers a non-surgical solution that effectively improves joint lubrication and reduces pain and stiffness.
The treatment's low invasiveness makes it highly attractive to elderly patients or those with medical conditions that make them unfit for surgery. It also enables quicker return to daily activities, which enhances patient satisfaction. Additionally, healthcare providers are recommending viscosupplements earlier in the treatment continuum, further boosting their adoption.
Increased awareness about early intervention and preventive care in managing osteoarthritis is also supporting the trend. As patient preferences shift toward less disruptive treatments, viscosupplementation presents a compelling choice, especially in outpatient and ambulatory care settings.
This trend is further strengthened by the growing availability of advanced hyaluronic acid formulations that offer longer-lasting relief with fewer injections, making the procedure even more appealing from both a clinical outcome and patient compliance perspective.
Restraints
- Limited Reimbursement Coverage
- Reimbursement limitations in some regions
-
High Cost of Viscosupplement Products - Despite their clinical benefits, many hyaluronic acid-based injections are priced at a premium, which can limit accessibility, particularly in cost-sensitive regions. Patients often require multiple injections over a treatment course, which adds to the overall financial burden.
In regions where insurance reimbursement is limited or absent, the out-of-pocket expense discourages patients from opting for viscosupplementation. Even in developed healthcare systems, reimbursement policies vary, and insurers may question the cost-effectiveness of repeated treatments, especially when long-term benefits are inconclusive in severe osteoarthritis cases.
The presence of alternative therapies such as NSAIDs, physical therapy, and corticosteroid injections, which are often more affordable, further hinders the wide-scale adoption of viscosupplementation. These treatments are usually the first line of defense, relegating viscosupplementation to second-line or optional treatment status.
Without significant pricing reforms or broader reimbursement support, the high cost of viscosupplements will continue to limit their uptake, particularly in low- and middle-income countries, and may deter patients from completing the full course of treatment.
Opportunities
- Expansion of Indications for Viscosupplementation
- Emerging Markets and Untapped Patient Populations
-
Development of Next-Generation Viscosupplements - Manufacturers are investing in advanced formulations that enhance the viscoelastic properties of hyaluronic acid, improve biocompatibility, and offer longer-lasting relief from joint pain. These innovations aim to improve clinical outcomes and reduce the frequency of injections.
New delivery mechanisms such as cross-linked HA, combination therapies with anti-inflammatory agents, and sustained-release systems are under active development. These improvements not only offer better pain relief but also address concerns related to treatment durability and injection-site discomfort. Such advances are expected to attract both physicians and patients toward viscosupplementation as a preferred intervention.
In addition, the use of biotechnology and personalized medicine approaches is opening new frontiers. Customized viscosupplements based on patient-specific joint conditions and biomarker analysis could potentially deliver more targeted and effective treatment, improving both efficacy and patient compliance.
These technological developments, combined with increasing support for clinical trials and regulatory approvals, are expected to transform the market. Companies that can offer innovative, evidence-backed, and cost-effective next-generation viscosupplements will likely gain a competitive advantage in the evolving therapeutic landscape.
Viscosupplementation Market Competitive Landscape Analysis
Key players in Viscosupplementation Market include:
- Anika Therapeutics
- Sanofi
- Fidia Farmaceutici
- Seikagaku Corporation
- Bioventus
- Ferring Pharmaceuticals
- Zimmer Biomet
- Smith & Nephew
- F.Hoffmann‑La Roche (Roche)
- DePuy Synthes (Johnson & Johnson)
- Lifecore Biomedical
- LG Life Sciences
- Avanos Medical
- APTISSEN
In this report, the profile of each market player provides following information:
- Company Overview and Product Portfolio
- Market Share Analysis
- Key Developments
- Financial Overview
- Strategies
- Company SWOT Analysis
- Introduction
- Research Objectives and Assumptions
- Research Methodology
- Abbreviations
- Market Definition & Study Scope
- Executive Summary
- Market Snapshot, By Dosage
- Market Snapshot, By Arthritis Type
- Market Snapshot, By Application
- Market Snapshot, By End User
- Market Snapshot, By Region
- Viscosupplementation Market Dynamics
- Drivers, Restraints and Opportunities
- Drivers
-
Growing geriatric population worldwide
-
Advancements in Viscosupplement Formulations
-
Increasing Preference for Minimally Invasive Treatment Options
-
-
Restraints
-
Limited Reimbursement Coverage
-
Reimbursement limitations in some regions
-
High Cost of Viscosupplement Products
-
- Opportunities
-
Expansion of Indications for Viscosupplementation
-
Emerging Markets and Untapped Patient Populations
-
Development of Next-Generation Viscosupplements
-
- Drivers
- PEST Analysis
- Political Analysis
- Economic Analysis
- Social Analysis
- Technological Analysis
- Porter's Analysis
- Bargaining Power of Suppliers
- Bargaining Power of Buyers
- Threat of Substitutes
- Threat of New Entrants
- Competitive Rivalry
- Drivers, Restraints and Opportunities
- Market Segmentation
- Viscosupplementation Market, By Dosage, 2021 - 2031 (USD Million)
-
Single Injection
-
Three Injection
-
Five Injection
-
- Viscosupplementation Market, By Arthritis Type, 2021 - 2031 (USD Million)
- Osteoarthritis
- Rheumatoid Arthritis
- Viscosupplementation Market, By Application, 2021 - 2031 (USD Million)
- Knee Osteoarthritis
- Hip Osteoarthritis
- Shoulder Osteoarthritis
- Others
- Viscosupplementation Market, By End User, 2021 - 2031 (USD Million)
-
Hospitals
-
Ambulatory Surgical Centers
-
Others
-
- Viscosupplementation Market, By Geography, 2021 - 2031 (USD Million)
- North America
- United States
- Canada
- Europe
- Germany
- United Kingdom
- France
- Italy
- Spain
- Nordic
- Benelux
- Rest of Europe
- Asia Pacific
- Japan
- China
- India
- Australia & New Zealand
- South Korea
- ASEAN (Association of South East Asian Countries)
- Rest of Asia Pacific
- Middle East & Africa
- GCC
- Israel
- South Africa
- Rest of Middle East & Africa
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- North America
- Viscosupplementation Market, By Dosage, 2021 - 2031 (USD Million)
- Competitive Landscape
- Company Profiles
- Anika Therapeutics
- Sanofi
- Fidia Farmaceutici
- Seikagaku Corporation
- Bioventus
- Ferring Pharmaceuticals
- Zimmer Biomet
- Smith & Nephew
- F.Hoffmann‑La Roche (Roche)
- DePuy Synthes (Johnson & Johnson)
- Lifecore Biomedical
- LG Life Sciences
- Avanos Medical
- APTISSEN
- Company Profiles
- Analyst Views
- Future Outlook of the Market